Estudio comparativo en el manejo médico del aborto terapéutico entre el uso de Mifepristone más Misoprostol y el uso de Misoprostol solo

Tuvo como objetivo evaluar las diferencias en el manejo médico del aborto terapéutico usando Mifepristone más Misoprostol comparado con el uso de Misoprostol solo. Se realizó un estudio observacional, de cohorte retrospectiva y multicéntrica (Instituto Nacional Materno Perinatal [INMP], Hospital Regional de Pucallpa, Hospital Santa Rosa de Piura y Hospital Regional de Loreto), en gestantes con indicación de aborto terapéutico, según lo establecido en la RM N° 486-2014-MINSA. Las pacientes enroladas en el INMP, al ingreso recibieron 200 mg de Mifepristona y a las 24 horas Misoprostol 800 μg colocado en fondo de saco vaginal posterior al cérvix, seguido de 400 μg vía sublingual, cada 3 horas hasta la expulsión del feto y placenta, siendo el tope 5 dosis por día; las pacientes de los tres hospitales restantes se les administro solo Misoprostol bajo el mismo esquema. El tiempo de expulsión del feto se consideró desde la administración de la primera dosis del misoprostol hasta las 24 horas; en el grupo de Mifepristona mas Misoprostol fue del 100% y en el grupo de Misoprostol solo fue del 83% (p = 0.05). La expulsión de la placenta en grupo que uso Mifepristona fue del 96% y en el grupo de Misoprostol solo fue del 83% (p = 0.20). Se presentaron restos endouterinos en el 10% del grupo de mifepristona versus 33% del grupo de solo misoprostol (p = 0.03). El tiempo de expulsión del producto de la concepción fue menor en el grupo de mifepristona con una diferencia de sus medianas de 2.8 horas (p =0.001). El estudio concluye que existen diferencias en el manejo médico del aborto terapéutico a favor del uso de Mifepristone más Misoprostol versus el uso de Misoprostol solo, en términos de tasa de éxito, tiempo de inducción al aborto y reacciones adversas o complicacione

Artificial Intelligence to Detect Papilledema from Ocular Fundus Photographs.

BACKGROUND: Nonophthalmologist physicians do not confidently perform direct ophthalmoscopy. The use of artificial intelligence to detect papilledema and other optic-disk abnormalities from fundus photographs has not been well studied. METHODS: We trained, validated, and externally tested a deep-learning system to classify optic disks as being normal or having papilledema or other abnormalities from 15,846 retrospectively collected ocular fundus photographs that had been obtained with pharmacologic pupillary dilation and various digital cameras in persons from multiple ethnic populations. Of these photographs, 14,341 from 19 sites in 11 countries were used for training and validation, and 1505 photographs from 5 other sites were used for external testing. Performance at classifying the optic-disk appearance was evaluated by calculating the area under the receiver-operating-characteristic curve (AUC), sensitivity, and specificity, as compared with a reference standard of clinical diagnoses by neuro-ophthalmologists. RESULTS: The training and validation data sets from 6779 patients included 14,341 photographs: 9156 of normal disks, 2148 of disks with papilledema, and 3037 of disks with other abnormalities. The percentage classified as being normal ranged across sites from 9.8 to 100%; the percentage classified as having papilledema ranged across sites from zero to 59.5%. In the validation set, the system discriminated disks with papilledema from normal disks and disks with nonpapilledema abnormalities with an AUC of 0.99 (95% confidence interval [CI], 0.98 to 0.99) and normal from abnormal disks with an AUC of 0.99 (95% CI, 0.99 to 0.99). In the external-testing data set of 1505 photographs, the system had an AUC for the detection of papilledema of 0.96 (95% CI, 0.95 to 0.97), a sensitivity of 96.4% (95% CI, 93.9 to 98.3), and a specificity of 84.7% (95% CI, 82.3 to 87.1). CONCLUSIONS: A deep-learning system using fundus photographs with pharmacologically dilated pupils differentiated among optic disks with papilledema, normal disks, and disks with nonpapilledema abnormalities. (Funded by the Singapore National Medical Research Council and the SingHealth Duke-NUS Ophthalmology and Visual Sciences Academic Clinical Program.)

Intracranial Hypertension Caused by an Ependymoma of the Lumbar Thecal Sac with Normal Cerebrospinal Fluid Composition

Tumors in the spinal canal are a rare but well-known cause of intracranial hypertension. Possible pathophysiologic mechanisms include disruption of CSF absorption at the arachnoid granulations due to high protein or degradation products in the CSF or blockage of cerebrospinal fluid (CSF) outflow from tumors

Magnetic Resonance Imaging as a Diagnostic Tool in Internuclear Ophthalmoplegia

Lesions affecting the medial longitudinal fasciculus (MLF) cause internuclear ophthalmoplegia (INO). Magnetic resonance imaging (MRI) is the ideal modality for visualizing detailed structures of the brainstem

Infliximab-Associated Retrobulbar Optic Neuritis

Infliximab is a tumor necrosis factor blocker that has been approved for the treatment of Crohn's disease and rheumatoid arthritis. A single case of retrobulbar optic neuritis associated with Infliximab has been recently reported. In this case the patient developed a superior visual field defect

Early Bilateral External Ophthalmoplegia Caused by Metastatic Breast Carcinoma

Breast cancer is the most frequent type of metastasis to the orbit, which although rare is a well recognized occurrence. Involvement of extraocular muscles is usually discrete and unilateral. Furthermore, other systemic metastases are usually encountered at the time of orbital compromise and occur after the original diagnosis of breast cancer is made

Multiple Intracranial Lesions Following Treatment of Nelson's Symptoms (MRI)

Declining cognition; Alexia; AgraphiaA 75-year old female with no light perception OD and right third, fourth and sixth nerve pareses. Previous history significant for diabetes mellitus, hypertension, Cushing syndrome and Nelson syndrome. After CD Dx, a bilateral adrenalectomy was performed.VA: NLP OD, 20/40 OS; Color plates: Unable to identify OS, Colors of large objects OD; RADP ODMRIPituitary carcinomaSurgery; XRT1. Grua JR and Nelson DH: ACTH-Producing Pituitary Tumors. Endocrinol Metab Clin North Am 1991; 20: 319-62. 2. Pernicone PJ, Bernd WS, Sebo TJ, et al: Pituitary Carcinoma Cancer 1997; 79(4): 804-12. 3. Kemink SA, Wesseling P, Pieters GF, et al: Progression of a Nelson's Adenoma to Pituitary Carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22(1): 70-5. 4. Kemink L, Picters G, Hermus A, Smals A, Kloppenborg P: Patient's Age is a Simple Predictive Factor for the development of Nelson's Syndrome after Total Adrenalectomy for Cushing's Disease. J Clin Endocrinol Metab 1994; 79(3): 887-9. 5. Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO: ACTH-Producing Pituitary Carcinoma Presenting as the Cauda Equina Syndrome. Arch Pathol Lab Med 1995; 199(1): 93-6. 6. Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR: Adrenocorticotropin-Producing Pituitary Carcinoma with Liver Metastatis. J Endocrinol Invest 1997; 20(4): 230-6. 7. Buchfelder M, Fahlbusch R, Thierauf P, Muller OA: Observations on the Pathophysiology of Nelson's Syndrome: A Report of Three Cases. Neurosurgery 1990; 27(6): 961-8. 8. Saegler W, Geisler F, Ludecke DK: Pituitary Pathology in Cushing's Disease. Path Res Pract 1988; 183: 592-5. 9. Favia G, Boscaro M, Lumachi F, D'Amico DF: Role of Bilateral Adrenaletomy in Cushing's Disease. World J Surg 1994; 18:462-6

Multiple Intracranial Lesions Following Treatment of Nelson's Symptoms (Pathology)

Declining cognition; Alexia; AgraphiaA 75-year old female with no light perception OD and right third, fourth and sixth nerve pareses. Previous history significant for diabetes mellitus, hypertension, cushing syndrome and Nelson syndrome. After CD Dx, a bilateral adrenalectomy was performed.VA: NLP OD, 20/40 OS; Color plates: Unable to identify OS, Color of large objects OD; RAPD ODMRIPituitary carcinomaSurgery; XRT1. Grua JR and Nelson DH: ACTH-Producing Pituitary Tumors. Endocrinol Metab Clin North Am 1991; 20: 319-62. 2. Pernicone PJ, Bernd WS, Sebo TJ, et al: Pituitary Carcinoma Cancer 1997; 79(4): 804-12. 3. Kemink SA, Wesseling P, Pieters GF, et al: Progression of a Nelson's Adenoma to Pituitary Carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22(1): 70-5. 4. Kemink L, Picters G, Hermus A, Smals A, Kloppenborg P: Patient's Age is a Simple Predictive Factor for the development of Nelson's Syndrome after Total Adrenalectomy for Cushing's Disease. J Clin Endocrinol Metab 1994; 79(3): 887-9. 5. Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO: ACTH-Producing Pituitary Carcinoma Presenting as the Cauda Equina Syndrome. Arch Pathol Lab Med 1995; 199(1): 93-6. 6. Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR: Adrenocorticotropin-Producing Pituitary Carcinoma with Liver Metastatis. J Endocrinol Invest 1997; 20(4): 230-6. 7. Buchfelder M, Fahlbusch R, Thierauf P, Muller OA: Observations on the Pathophysiology of Nelson's Syndrome: A Report of Three Cases. Neurosurgery 1990; 27(6): 961-8. 8. Saegler W, Geisler F, Ludecke DK: Pituitary Pathology in Cushing's Disease. Path Res Pract 1988; 183: 592-5. 9. Favia G, Boscaro M, Lumachi F, D'Amico DF: Role of Bilateral Adrenaletomy in Cushing's Disease. World J Surg 1994; 18:462-6

Multiple Intracranial Lesions Following Treatment of Nelson's Symptoms

Cognitive decline; Alexia with agraphiaA 75-year old female with no light perception OD and right third, fourth and sixth nerve pareses. Previous history significant for diabetes mellitus, hypertension, Cushing syndrome and Nelson syndrome. After CD Dx, a bilateral adrenalectomy was performed.VA: NLP OD, 20/40 OS; Color plates: Unable to identify OS, Colors of large objects OD; RAPD ODMRIPituitary carcinomaSurgery; XRT1. Grua JR and Nelson DH: ACTH-Producing Pituitary Tumors. Endocrinol Metab Clin North Am 1991; 20: 319-62. 2. Pernicone PJ, Bernd WS, Sebo TJ, et al: Pituitary Carcinoma Cancer 1997; 79(4): 804-12. 3. Kemink SA, Wesseling P, Pieters GF, et al: Progression of a Nelson's Adenoma to Pituitary Carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22(1): 70-5. 4. Kemink L, Picters G, Hermus A, Smals A, Kloppenborg P: Patient's Age is a Simple Predictive Factor for the development of Nelson's Syndrome after Total Adrenalectomy for Cushing's Disease. J Clin Endocrinol Metab 1994; 79(3): 887-9. 5. Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO: ACTH-Producing Pituitary Carcinoma Presenting as the Cauda Equina Syndrome. Arch Pathol Lab Med 1995; 199(1): 93-6. 6. Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR: Adrenocorticotropin-Producing Pituitary Carcinoma with Liver Metastatis. J Endocrinol Invest 1997; 20(4): 230-6. 7. Buchfelder M, Fahlbusch R, Thierauf P, Muller OA: Observations on the Pathophysiology of Nelson's Syndrome: A Report of Three Cases. Neurosurgery 1990; 27(6): 961-8. 8. Saegler W, Geisler F, Ludecke DK: Pituitary Pathology in Cushing's Disease. Path Res Pract 1988; 183: 592-5. 9. Favia G, Boscaro M, Lumachi F, D'Amico DF: Role of Bilateral Adrenaletomy in Cushing's Disease. World J Surg 1994; 18:462-6

Multiple Intracranial Lesions Following Treatment of Nelson's Symptoms: (MRI)

Declining cognition; Alexia; AgraphiaA 75-year old female with no light perception OD and right third, fourth and sixth nerve pareses. Previous history significant for diabetes mellitus, hypertension, cushing syndrome and Nelson syndrome. After CD Dx, a bilateral adrenalectomy was performed.VA: NLP OD, 20/40 OS; Color plates: Unable to identify OS, Colors of large objects OD; RAPD ODMRIPituitary carcinomaSurgery; XRT1. Grua JR and Nelson DH: ACTH-Producing Pituitary Tumors. Endocrinol Metab Clin North Am 1991; 20: 319-62. 2. Pernicone PJ, Bernd WS, Sebo TJ, et al: Pituitary Carcinoma Cancer 1997; 79(4): 804-12. 3. Kemink SA, Wesseling P, Pieters GF, et al: Progression of a Nelson's Adenoma to Pituitary Carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22(1): 70-5. 4. Kemink L, Picters G, Hermus A, Smals A, Kloppenborg P: Patient's Age is a Simple Predictive Factor for the development of Nelson's Syndrome after Total Adrenalectomy for Cushing's Disease. J Clin Endocrinol Metab 1994; 79(3): 887-9. 5. Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO: ACTH-Producing Pituitary Carcinoma Presenting as the Cauda Equina Syndrome. Arch Pathol Lab Med 1995; 199(1): 93-6. 6. Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR: Adrenocorticotropin-Producing Pituitary Carcinoma with Liver Metastatis. J Endocrinol Invest 1997; 20(4): 230-6. 7. Buchfelder M, Fahlbusch R, Thierauf P, Muller OA: Observations on the Pathophysiology of Nelson's Syndrome: A Report of Three Cases. Neurosurgery 1990; 27(6): 961-8. 8. Saegler W, Geisler F, Ludecke DK: Pituitary Pathology in Cushing's Disease. Path Res Pract 1988; 183: 592-5. 9. Favia G, Boscaro M, Lumachi F, D'Amico DF: Role of Bilateral Adrenaletomy in Cushing's Disease. World J Surg 1994; 18:462-6